Figures & data
Figure 1. Flowchart of cohort selection.
Table 1. Baseline characteristics of the study cohort of 10,287 initiators of aspirin and their time-conditional propensity score matched nonusers, among patients with COPD, with the corresponding standardized mean differences.
Figure 2. Kaplan–Meir curves and cumulative incidences comparing acetylsalicylic acid (ASA) use (red) with nonuse (blue), in patients with COPD in the first year after treatment initiation on: (A) All-cause mortality; (B) Severe exacerbation; and (C) Moderate or severe exacerbation.
Table 2. Adjusted HRs of all-cause mortality and COPD exacerbation, comparing ASA use with nonuse in patients with COPD in the first year after treatment initiation, from the as-treated analysis.
Table 3. Adjusted HRs of all-cause mortality and COPD exacerbation, comparing ASA use with nonuse in patients with COPD in the first year after treatment initiation, stratified by platelet count at baseline (among subjects with platelet count), from the as-treated analysis.
Table 4. Adjusted HRs of all cause-mortality, from sensitivity analyses and stratified by prior cardiovascular disease (CVD), by other antiplatelet, and restricting to patients with FEV1/FVC < lower limit of normal (LLN), comparing ASA use with nonuse in patients with COPD in the first year after treatment initiation.